According to the Telegraph, Heineken has begun advising UK pubs to adapt to the spread of GLP-1 weight-loss medications by promoting half-pints, low and no-alcohol beer, and smaller food pairings. A known effect of these drugs is a sharp drop in appetite and in the desire to drink, which means a meaningful and growing group of customers are showing up wanting the night out but ordering fewer rounds, smaller portions, and lower-strength drinks.
The significance is in who is noticing and why. This is not a wellness campaign or a Dry January nudge; it is a major brewer treating a pharmaceutical trend as a structural change in demand and telling its accounts to retool the menu around it. A customer whose body no longer wants a second pint is not a lost sale. They are a different sale, and the venues that recognize it early will keep them.
The Cr(af)ted Take
This is the occasion-expansion story arriving through an unexpected door. Whatever one thinks of the drugs, their effect on drinking points in the same direction as every other trend we track: people still want to go out, they just want less alcohol while they do. GLP-1 simply makes that preference physiological rather than philosophical, and it is creating a wave of drinkers who need the lighter option to be good, because for them it is the only option that will go down easily.
For anyone pouring drinks, the instruction is the same one we keep arriving at from every angle: have a real alcohol-free choice ready, and make it worth ordering. The GLP-1 customer is the moderation customer in sharp relief, present, social, spending, and genuinely uninterested in a third drink. A half-pint helps. A great alcohol-free cocktail or beer helps more, because it lets them order a second and third round of something, which is exactly what keeps them at the table and the till ringing.
Original reporting: The Telegraph →